Semi-Annual Report (Unaudited) CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF (A Sub-Fund of China Universal International ETF Series, an umbrella unit trust established under the laws of Hong Kong) For the period from 1 January 2016 to 30 June 2016 CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF (A Sub-Fund of China Universal International ETF Series) CONTENTS Pages MANAGEMENT AND ADMINISTRATION 1 STATEMENT OF FINANCIAL POSITION 2 STATEMENT OF COMPREHENSIVE INCOME 3 STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS 4 INVESTMENT PORTFOLIO (UNAUDITED) 5 - 7 MOVEMENTS IN INVESTMENT PORTFOLIO (UNAUDITED) 8 - 10 PERFORMANCE RECORD (UNAUDITED) 11 0 CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF (A Sub-Fund of China Universal International ETF Series) MANAGEMENT AND ADMINISTRATION MANAGER AND RQFII HOLDER SERVICE AGENT OR CONVERSION AGENT China Universal Asset Management (Hong Kong) Company HK Conversion Agency Services Limited Limited 2nd Floor, Infinitus Plaza 3710-11, Two International Finance Centre 199 Des Voeux Road Central 8 Finance Street Hong Kong Central Hong Kong AUDITORS Ernst & Young DIRECTORS OF THE MANAGER 22/F, CITIC Tower LI Wen 1 Tim Mei Avenue WAN Qing Central ZHANG Hui Hong Kong ADVISER TRUSTEE China Universal Asset Management Company Limited BOCI-Prudential Trustee Limited 22/F, Aurora Plaza 12/F & 25/F, Citicorp Centre No. 99 Fucheng Road 18 Whitfield Road Pudong District Causeway Bay Shanghai 200120 Hong Kong China CUSTODIAN RQFII CUSTODIAN Bank of China (Hong Kong) Limited Bank of China Limited 14/F, Bank of China Tower No. 1, Fuxingmen Nei Dajie 1 Garden Road Beijing 100818 Central China Hong Kong LEGAL ADVISER TO THE MANAGER REGISTRAR Deacons Computershare Hong Kong Investor Services 5th Floor, Alexandra House Limited 18 Chater Road 46th Floor, Hopewell Centre Central 183 Queen's Road East Hong Kong Wan Chai Hong Kong 1 CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF (A Sub-Fund of China Universal International ETF Series) STATEMENT OF FINANCIAL POSITION 30 June 2016 31 December 2015 RMB RMB (Unaudited) (Audited) ASSETS Financial assets at fair value through profit or loss 32,572,178 39,737,907 Prepayment and other receivables 6,589 12,832 Cash and bank balances 917,374 597,410 Deposit reserve-China Exchange Clearing __________8,046 __________8,102 TOTAL ASSETS __________33,504,187 __________40,356,251 LIABILITIES Trustee and custodian fees payable 10,000 3,396 Withholding tax provision 164 10,072 Other payables and accruals __________138,610 __________213,532 TOTAL LIABILITIES __________148,774 __________227,000 EQUITY NET ASSETS ATTRIBUTABLE TO UNITHOLDERS __________33,355,413 __________40,129,251 NUMBER OF UNITS IN ISSUE __________2,100,000 __________2,100,000 NET ASSET VALUE PER UNIT __________15.8835 __________19.1092 2 CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF (A Sub-Fund of China Universal International ETF Series) STATEMENT OF COMPREHENSIVE INCOME For the period from For the period from 1 January 2016 to 1 January 2015 to 30 June 2016 30 June 2015 RMB RMB (Unaudited) (Unaudited) INCOME Dividend income 177,301 206,862 Interest income __________665 __________3,066 __________177,966 __________209,928 EXPENSES Management fee - (88,061) Brokerage commission (3,441) (19,671) Trustee and custodian fees (30,841) (17,612) Auditors' remuneration (93,623) (81,719) Index licensing fee (50,000) (50,000) Professional fee (78,724) (56,133) Other operating expenses __________(130,328) __________(176,645) __________(386,957) __________(489,841) (LOSS) BEFORE INVESTMENT AND EXCHANGE DIFFERENCES (208,991) (279,913) INVESTMENT AND EXCHANGE DIFFERENCES Net change in unrealised (losses)/gains on financial assets at fair value through profit or loss (5,721,650) 2,388,995 Net realised (losses)/gains on financial assets at fair value through profit or loss __________(814,725) __________7,547,072 NET INVESTMENTS AND EXCHANGE (LOSSES)/GAINS __________(6,536,375) __________9,936,067 (LOSS)/PROFIT BEFORE TAX (6,745,366) 9,656,154 Withholding tax __________(28,472) __________(23,859) (LOSS)/PROFIT AFTER TAX AND TOTAL COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD __________(6,773,838) __________9,632,295 3 CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF (A Sub-Fund of China Universal International ETF Series) STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS For the period from 1 January 2015 to 30 June 2015 RMB (Unaudited) At 31 December 2014 & 1 January 2015 21,263,043 Subscription of units 48,246,939 Redemption of units (21,941,523) Total comprehensive income for the period ____________9,632,295 At 30 June 2015 ____________57,200,754 For the period from 1 January 2016 to 30 June 2016 RMB (Unaudited) At 31 December 2015 & 1 January 2016 40,129,251 Subscription of units - Redemption of units - Total comprehensive loss for the period ____________(6,773,838) At 30 June 2016 ____________33,355,413 4 CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF (A Sub-Fund of China Universal International ETF Series) INVESTMENT PORTFOLIO (Unaudited) As at 30 June 2016 Market Holdings Value % of Shares RMB NAV Financial assets at fair value through profit or loss Listed Securities China (100%) Health Care AIER EYE HOSPITAL GROUP CO LTD-A 17,164 627,001 1.88% BEIJING SL PHARMACEUTICAL CO LTD-A 17,928 541,067 1.62% BEIJING TIANTAN BIOLOGICAL PRODUCTS CORP LTD-A 11,200 311,248 0.93% BEIJING TONGRENTANG CO LTD-A 29,547 880,205 2.64% CHANGCHUN HIGH & NEW TECHNOLOGY INDUSTRIES (GROUP) INC-A 5,980 637,947 1.91% CHINA ANIMAL HUSBANDRY INDUSTRY CO LTD -A 9,100 166,530 0.50% CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO LTD-A 15,738 286,746 0.86% CHINA RESOURCES SANJIU MEDICAL & PHARMACEUTICAL CO LTD-A 17,100 414,162 1.24% DA AN GENE CO LTD SUN YAT-SEN UNIVERSITY-A 22,154 615,881 1.85% GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD -A 19,300 231,407 0.69% GUANGXI WUZHOU ZHONGHENG GROUP CO LTD-A 109,500 475,230 1.42% GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HLDGS CO LTD-A 23,400 576,576 1.73% GUIZHOU BAILING GROUP PHARMACEUTICAL CO LTD- A 18,200 313,040 0.94% GUIZHOU XINBANG PHARMACEUTICAL CO LTD -A 29,400 271,656 0.81% GUIZHOU YIBAI PHARMACEUTICAL CO LTD-A 25,400 405,892 1.22% HAINAN HAIYAO CO LTD-A 38,074 415,387 1.25% HARBIN GLORIA PHARMACEUTICALS CO LTD-A 38,931 338,700 1.02% HARBIN PHARMACEUTICAL GROUP CO LTD-A 64,400 533,876 1.60% HEILONGJIANG ZBD PHARMACEUTICAL CO LTD-A 7,200 157,320 0.47% HUALAN BIOLOGICAL ENGINEERING INC -A 20,256 636,038 1.91% HUMANWELL HEALTHCARE GROUP CO LTD -A 39,180 657,049 1.97% HYBIO PHARMACEUTICAL CO LTD-A 19,400 394,790 1.18% JIANGSU HENGRUI MEDICINE CO LTD-A 62,620 2,511,688 7.53% JIANGSU KANION PHARMACEUTICAL CO LTD-A 18,600 303,738 0.91% JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO LTD-A 12,600 399,672 1.20% JIANGZHONG PHARMACEUTICAL CO LTD-A 7,800 248,040 0.74% JILIN AODONG MEDICINE INDUSTRY GROUPS CO LTD -A 30,828 769,159 2.31% JILIN ZIXIN PHARMACEUTICAL INDUSTRIAL CO LTD-A 11,200 164,640 0.49% JINLING PHARMACEUTICAL CO LTD-A 13,100 171,479 0.51% JINYU BIO-TECHNOLOGY CO LTD-A 25,004 683,359 2.05% JOINCARE PHARMACEUTICAL GROUP INDUSTRY CO LTD-A 28,300 259,794 0.78% KUNMING PHARMACEUTICAL CORP-A 24,200 330,088 0.99% 5 CHINA UNIVERSAL INTERNATIONAL ETF SERIES – C-SHARES CSI HEALTHCARE INDEX ETF (A Sub -Fund of China Universal International ETF Series) INVESTMENT PORTFOLIO (Unaudited) (Continued) As at 30 June 2016 Market Holdings Value % of Shares RMB NAV Financial assets at fair value through profit or loss (Continued) Listed Securities China (100%) Health Care (Continued) LEPU MEDICAL TECHNOLOGY BEIJING CO LTD-A 37,600 685,824 2.06% LIVZON PHARMACEUTICAL GROUP INC-A 5,480 252,683 0.76% MAYINGLONG PHAHRMACEUTICAL GROUP CO LTD-A 13,000 270,790 0.81% NORTH CHINA PHARMACEUTICAL CO LTD-A 35,200 218,592 0.66% SHANDONG DONG-E E-JIAO CO LTD-A 22,435 1,185,241 3.55% SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD -A 49,800 947,196 2.84% SHANGHAI HAIXIN GROUP CO-A 31,800 423,258 1.27% SHANGHAI KAIBAO PHARMACEUTICAL CO LTD-A 21,560 219,265 0.66% SHANGHAI KEHUA BIO-ENGINEERING CO LTD-A 17,891 381,257 1.14% SHANGHAI KINGSTAR WINNING SOFTWARE CO LTD-A 24,500 605,150 1.81% SHANGHAI RAAS BLOOD PRODUCTS CO LTD-A 23,904 900,703 2.70% SHENZHEN GLORY MEDICAL CO LTD-A 9,538 222,999 0.67% SHENZHEN HEPALINK PHARMACEUTICAL CO LTD -A 16,800 293,328 0.88% SHENZHEN SALUBRIS PHARMACEUTICALS CO LTD-A 13,700 372,640 1.12% SHIJIANGZHUANG YILING PHARMACEUTICAL CO LTD-A 19,600 311,836 0.93% SHINVA MEDICAL INSTRUMENT CO LTD-A 12,400 286,316 0.86% SICHUAN KELUN PHARMACEUTICAL CO LTD-A 37,502 577,906 1.73% TASLY PHARMACEUTICAL GROUP CO LTD-A 28,000 1,001,280 3.00% TIANJIN CHASE SUN PHARMACEUTICAL CO LTD -A 22,400 389,536 1.17% TIANJIN ZHONGXIN PHARMACEUTICAL GROUP CORP LTD-A 10,000 172,700 0.52% TONGHUA DONGBAO PHARMACEUTICAL CO LTD-A 41,520 859,049 2.58% XIANGXUE PHARMACEUTICAL CO LTD-A 20,580 303,143 0.91% YABAO PHARMACEUTICAL GROUP CO LTD-A 24,130 242,024 0.73% YUNNAN BAIYAO GROUP CO LTD -A 22,500 1,446,750 4.34% ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO LTD-A 13,000 585,130 1.75% ZHEJIANG CONBA PHARMACEUTICAL CO LTD-A 55,755 361,292 1.08% ZHEJIANG DIAN DIAGNOSTICS CO LTD-A 14,100 465,018 1.39% ZHEJIANG HISUN PHARMACEUTICAL CO LTD-A 22,115 268,697 0.81% ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD-A 27,040 657,613 1.97% ZHEJIANG MEDICINE CO LTD-A 28,300 373,277 1.12% ZHEJIANG NHU CO LTD -A 23,696 500,697 1.50% ZHEJIANG XIANJU PHARMACEUTICAL